Amicus Therapeutics Inc.
Amicus Therapeutics Resolves Patent Litigation with Teva
Summary
On October 15, 2024, Amicus Therapeutics, Inc. and its subsidiary entered into a license agreement with Teva Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc. to resolve patent litigation over the submission of a generic version of Galafold. The agreement grants Teva a non-exclusive, royalty-free license to commercialize its generic Galafold in the U.S., with the option to commence earlier under certain conditions. The litigation will be terminated upon court approval of the consent judgment and permanent injunction. The agreement requires filings with the Federal Trade Commission and the Department of Justice, as applicable. Similar litigation continues against Aurobindo, with a litigation stay in place for Lupin.
Profitelligence Alerts
Get alerts for FOLD
Be first to know when Amicus Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Amicus Therapeutics Inc.
Amicus Therapeutics Inc. is a biopharmaceutical company dedicated to developing advanced therapies for rare and orphan diseases. Its primary focus is on genetic disorders, particularly lysosomal storage disorders and other diseases resulting from improper protein folding within cells. Amicus leverages its proprietary technology platforms to create drug candidates that address unmet medical needs, providing innovative solutions for complex conditions like Fabry disease and Pompe disease. The company's commitment to patient-centric innovation aims to enhance the quality of life for individuals facing challenging health diagnoses. Situated within the biotechnology sector, Amicus plays a significant role in advancing novel treatment options, thereby impacting healthcare markets and potentially transforming the standard of care for rare genetic diseases. Founded in 2002, the company harnesses cutting-edge research and collaborations to foster groundbreaking developments in the therapeutic landscape uniquely shaped by the complexities of rare diseases.
Official SEC Documents
Advertisement